Allurion shares surge 20.93% intraday on 23% weight loss data combining balloon and tirzepatide.

Allurion Technologies Inc. surged 20.93% intraday following the release of positive clinical data showing patients using its Smart Capsule balloon in combination with low-dose tirzepatide achieved an average 23% total body weight loss and 14% lean mass gain over 12 months. The results address key limitations of GLP-1 medications, such as muscle wasting and adherence issues, and highlight the potential of the combination therapy to enhance weight loss outcomes. The study, involving 76 patients, underscores the company’s innovative approach and aligns with its plans for a prospective clinical trial. Despite a significant Q3 2025 revenue decline and an 89% year-to-date stock drop, the intraday rally reflects investor optimism over the novel therapy’s market differentiation and therapeutic benefits.